Early Access: Sable

As we age, fat cells don't multiply. They enlarge up to 4x their original size, becoming metabolically sluggish and increasingly resistant to diet and exercise. Sable’s product does not tighten skin temporarily, or create the optical illusion of a slimmer silhouette, but instead directly targets fat at the cellular level.

Sable is a New York-based company operating at the intersection of biotech and beauty that has developed a topical body cream that actually reduces the volume of fat cells.

The modern body care aisle is full of promises. Products like firming creams, sculpting serums, and contouring gels are typically built using the same handful of ingredients, like caffeine and green tea. However, these typical ingredients do not address the underlying biology of why stubborn fat exists in the first place.

Sable does. The product’s core ingredient, currently referred to as SBL-001, is a bioengineered nanomaterial originally developed at Columbia University Medical Center that penetrates fat cells and directly inhibits lipid synthesis. In preclinical studies, it demonstrated up to a 70% reduction in fat cell volume, making waves in the quest for a new category of localized, non-invasive fat reduction.

Read More in the Early Access by Coeus Collective Newsletter